These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 35512743)

  • 21. Influence of CYP2C19 genotypes for the effect of 1-month dual antiplatelet therapy followed by clopidogrel monotherapy relative to 12-month dual antiplatelet therapy on clinical outcomes after percutaneous coronary intervention: a genetic substudy from the STOPDAPT-2.
    Watanabe H; Morimoto T; Ogita M; Suwa S; Natsuaki M; Suematsu N; Koeda Y; Morino Y; Nikaido A; Hata Y; Doi M; Hibi K; Kimura K; Yoda S; Kaneko T; Nishida K; Kawai K; Yamaguchi K; Wakatsuki T; Tonoike N; Yamamoto M; Shimizu S; Shimohama T; Ako J; Kimura T;
    Cardiovasc Interv Ther; 2021 Oct; 36(4):403-415. PubMed ID: 33184726
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of Cytochrome P450 2C19*2 and *3 on Clopidogrel Loading Dose in Saudi Patients with Acute Coronary Syndrome.
    Khalaf H; Al Meman AA; Rasool S
    Drug Metab Lett; 2016; 10(1):65-70. PubMed ID: 26573281
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical outcomes of patients treated using very short duration dual antiplatelet therapy after implantation of biodegradable-polymer drug-eluting stents: rationale and design of a prospective multicenter REIWA registry.
    Ishida M; Takahashi F; Goto I; Niiyama M; Saitoh H; Sakamoto T; Maegawa Y; Osaki T; Nishiyama O; Endo H; Sakamoto R; Kojima T; Koeda Y; Kimura T; Itoh T; Morino Y;
    Cardiovasc Interv Ther; 2020 Oct; 35(4):398-404. PubMed ID: 32776221
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of the CYP2C19*17 Allele on Outcomes in Patients Receiving Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention.
    Lee CR; Thomas CD; Beitelshees AL; Tuteja S; Empey PE; Lee JC; Limdi NA; Duarte JD; Skaar TC; Chen Y; Cook KJ; Coons JC; Dillon C; Franchi F; Giri J; Gong Y; Kreutz RP; McDonough CW; Stevenson JM; Weck KE; Angiolillo DJ; Johnson JA; Stouffer GA; Cavallari LH;
    Clin Pharmacol Ther; 2021 Mar; 109(3):705-715. PubMed ID: 32897581
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Platelet Reactivity and Clinical Outcomes After Coronary Artery Implantation of Drug-Eluting Stents in Subjects With Peripheral Arterial Disease: Analysis From the ADAPT-DES Study (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents).
    Gupta R; Kirtane AJ; Ozan MO; Witzenbichler B; Rinaldi MJ; Metzger DC; Weisz G; Stuckey TD; Brodie BR; Mehran R; Ben-Yehuda O; Stone GW
    Circ Cardiovasc Interv; 2017 Mar; 10(3):. PubMed ID: 28288963
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High platelet reactivity strongly predicts early stent thrombosis in patients with drug-eluting stent implantation.
    Lim S; Hong SJ; Kim JH; Cha JJ; Joo HJ; Park JH; Yu CW; Kim BK; Chang K; Park Y; Song YB; Ahn SG; Suh JW; Lee SY; Cho JR; Her AY; Jeong YH; Kim HS; Kim MH; Shin ES; Lim DS;
    Sci Rep; 2024 Jan; 14(1):520. PubMed ID: 38177178
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interaction analysis between genetic polymorphisms and pharmacodynamic effect in patients treated with adjunctive cilostazol to dual antiplatelet therapy: results of the ACCEL-TRIPLE (Accelerated Platelet Inhibition by Triple Antiplatelet Therapy According to Gene Polymorphism) study.
    Kim IS; Jeong YH; Park Y; Yoon SE; Kwon TJ; Park JR; Hwang SJ; Koh EH; Kwak CH; Hwang JY; Kim S
    Br J Clin Pharmacol; 2012 Apr; 73(4):629-40. PubMed ID: 22007612
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pilot study of the antiplatelet effect of increased clopidogrel maintenance dosing and its relationship to CYP2C19 genotype in patients with high on-treatment reactivity.
    Barker CM; Murray SS; Teirstein PS; Kandzari DE; Topol EJ; Price MJ
    JACC Cardiovasc Interv; 2010 Oct; 3(10):1001-7. PubMed ID: 20965456
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of dual antiplatelet therapy prescribed as one-pill versus two-pill regimen. A pooled analysis of individual patient data from the three MR-CAPCIS trials.
    Lim WH; Chae IH; Yoon CH; Choi DJ; Lim SW; Park WJ; Doh JH; Kim SH; Kim MA; Lee SH; Yoon JH; Ahn YK; Hyon MS; Kim KS; Kim YK; Lee HC; Seol SH; Hwang KK; Choi SW; Han KR; Shin ES; Kim SW; Lee BK; Kim HS
    Thromb Haemost; 2016 Jul; 116(1):78-86. PubMed ID: 27029284
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Proton Pump Inhibitors, Platelet Reactivity, and Cardiovascular Outcomes After Drug-Eluting Stents in Clopidogrel-Treated Patients: The ADAPT-DES Study.
    Weisz G; Smilowitz NR; Kirtane AJ; Rinaldi MJ; Parvataneni R; Xu K; Stuckey TD; Maehara A; Witzenbichler B; Neumann FJ; Metzger DC; Henry TD; Cox DA; Duffy PL; Brodie BR; Mazzaferri EL; Mehran R; Stone GW
    Circ Cardiovasc Interv; 2015 Oct; 8(10):. PubMed ID: 26458411
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clopidogrel response variability is associated with endothelial dysfunction in coronary artery disease patients receiving dual antiplatelet therapy.
    Siasos G; Oikonomou E; Zaromitidou M; Kioufis S; Kokkou E; Mourouzis K; Vlasis K; Vavuranakis M; Stone PH; Papavassiliou AG; Tousoulis D
    Atherosclerosis; 2015 Sep; 242(1):102-8. PubMed ID: 26188531
    [TBL] [Abstract][Full Text] [Related]  

  • 32. First analysis of the relation between CYP2C19 genotype and pharmacodynamics in patients treated with ticagrelor versus clopidogrel: the ONSET/OFFSET and RESPOND genotype studies.
    Tantry US; Bliden KP; Wei C; Storey RF; Armstrong M; Butler K; Gurbel PA
    Circ Cardiovasc Genet; 2010 Dec; 3(6):556-66. PubMed ID: 21079055
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of Cytochrome P450 2C19 Reduced-Function Polymorphism on Lesions and Clinical Outcome in Japanese Patients After Drug-eluting Stent Implantation.
    Tahara N; Shinke T; Otake H; Nishio R; Konishi A; Hirata KI
    Kobe J Med Sci; 2018 Sep; 64(2):E56-E63. PubMed ID: 30381727
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Defining predictive values using three different platelet function tests for CYP2C19 phenotype status on maintenance dual antiplatelet therapy after PCI.
    Zhang HZ; Kim MH; Han JY; Jeong YH
    Platelets; 2014; 25(4):285-91. PubMed ID: 23971745
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effect of CYP2C19 gene polymorphisms on the pharmacokinetics and pharmacodynamics of prasugrel 5-mg, prasugrel 10-mg and clopidogrel 75-mg in patients with coronary artery disease.
    Gurbel PA; Bergmeijer TO; Tantry US; ten Berg JM; Angiolillo DJ; James S; Lindahl TL; Svensson P; Jakubowski JA; Brown PB; Duvvuru S; Sundseth S; Walker JR; Small D; Moser BA; Winters KJ; Erlinge D
    Thromb Haemost; 2014 Sep; 112(3):589-97. PubMed ID: 25008027
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of Aspirin and Clopidogrel Hyporesponsiveness in Patients Treated With Drug-Eluting Stents: 2-Year Results of a Prospective, Multicenter Registry Study.
    Stuckey TD; Kirtane AJ; Brodie BR; Witzenbichler B; Litherland C; Weisz G; Rinaldi MJ; Neumann FJ; Metzger DC; Henry TD; Cox DA; Duffy PL; Mazzaferri EL; Gurbel PA; Mehran R; Généreux P; Ben-Yehuda O; Simonton CA; Stone GW;
    JACC Cardiovasc Interv; 2017 Aug; 10(16):1607-1617. PubMed ID: 28780034
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Paraoxonase-1 activity affects the clopidogrel response in CYP2C19 loss-of-function carriers.
    Nishio R; Shinke T; Otake H; Nakagawa M; Inoue T; Hariki H; Osue T; Taniguchi Y; Iwasaki M; Hiranuma N; Konishi A; Kinutani H; Kuroda M; Hirata K
    Thromb Res; 2013 Nov; 132(5):558-64. PubMed ID: 24080149
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of endothelial dysfunction on residual platelet aggregability after dual antiplatelet therapy with aspirin and clopidogrel in patients with stable coronary artery disease.
    Fujisue K; Sugiyama S; Ono T; Matsuzawa Y; Akiyama E; Sugamura K; Matsubara J; Kurokawa H; Kaikita K; Iwashita S; Sumida H; Hokimoto S; Oniki K; Nakagawa K; Matsui K; Ogawa H
    Circ Cardiovasc Interv; 2013 Aug; 6(4):452-9. PubMed ID: 23922147
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of the proton pump inhibitors and CYP2C19*2 polymorphism on platelet response to clopidogrel as assessed by four platelet function assays.
    Tsantes AE; Ikonomidis I; Papadakis I; Bonovas S; Gialeraki A; Kottaridi C; Kyriakou E; Kokori S; Douramani P; Kopterides P; Karakitsos P; Lekakis J; Kapsimali V
    Thromb Res; 2013 Aug; 132(2):e105-11. PubMed ID: 23830212
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Determinants of high on-treatment platelet reactivity and agreement between VerifyNow and Multiplate assays.
    Danielak D; Komosa A; Tomczak A; Graczyk-Szuster A; Lesiak M; Główka F; Karaźniewicz-Łada M
    Scand J Clin Lab Invest; 2017 May; 77(3):190-198. PubMed ID: 28276728
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.